Somatropin HGH

Somatropin HGH was discovered through medical research that emerged in the 1980's, enabling researchers to splice human genes. The process of gene splicing allowed researchers to clone Somatropin HGH identifying its exact sequence of human DNA structure of the human body of 191 Amino acids.

In 1985 Somatropin HGH expert Keith Kelley, M.D. demonstrated that injections of cells that secrete high amounts of Somatropin hgh could cause the thymus glands in mature rats to grow until they became as large and healthy as those of young rats.

The thymus gland is the primary organ of the immune system. When levels of Somatropin HGH are increased throughout the immune system, it sets off the following reactions: increased maturation of neutrophils, higher activity of natural killer cells, stimulation of macrophages, increased production of red blood cells, production of new antibodies, increased production of T-cells and interleukin 2, and the greater proliferation and activity of lymphocyte cells.

Somatropin HGH was identical to that of the human DNA, it was then produced in drug laboratories in commercial quantities. Consequentially, biosynthetic somatropin (hgh) began to be available to medical researchers for the first time. This recombinant somatropin is completely identical to the somatropin/IGF-1 naturally produced by the human pituitary gland, and is therefore referred to as a natural Bio Synthetic hormone which the body naturally produces.

In the mid-1980's, cadaver Somatropin HGH was pulled off the market after it was found to cause a rare disease called Creutzfe. Dr. Daniel Rudman, an endocrinologist and medical researcher from Madison, Wisconsin, conducted the original research on the effect of Somatropin HGH in humans. Dr. Rudman believed that changes in body composition which become apparent at age 35 had to do with declining hormone levels. The only method of testing his hypothesis was to replace Somatropin in deficient elderly adults to determine if the HGH reversed the effects of aging.

To test his theory, Dr. Rudman began a study by replacing Somatropin HGH Human Growth Hormone in a group of older men to examine its effects on lean body mass and body fat in elderly adults. Dr. Rudman studied 26 men between the ages of 61 and 80 who had experienced significant adverse changes in body composition with age, but who were otherwise healthy. These men were overweight and had significantly low levels of Somatropin HGH.

Dr. Rudman selected Somatropin hgh injections for sale as the initial hormone to be replaced. He was aware that the decline in Somatropin HGH after age 35 was accompanied by an increase in body fat and a decline in lean muscle mass. The men in the study who received Somatropin replacement gained an average of 9% in lean muscle mass while losing 14% of body fat during the six-month test. Bone density increased and their skin also became thicker and firmer.

According to Rudman, these particular men experienced a reverse aging effect by 10 to 20 years. Dr. Rudman concluded, "The overall deterioration of the body that comes with growing old is not inevitable." Rudman's study, published in The New England Journal of Medicine in 1990, constituted a tremendous scientific breakthrough in the field of rejuvenation medicine.

Dr. Rudman inspired research scientists and physicians worldwide to investigate and research the use of Somatropin human growth hormone replacement therapy to reverse the effects of aging and treat diseases associated with aging. Concurrent with the time of Dr. Rudman's study, medical researchers in England, Sweden and Denmark were also discovering with consistency the remarkable effects of Somatropin on preventing aging and reversing aging.

Providing those with Somatropin hgh deficiency from pituitary disease with hormone replacement had a remarkable impact. Results included an increase in mood and energy and even reversed heart failure according to the New England Journal of Medicine in 1996.

In August 1996, The Food and Drug Administration approved the use of Somatropin in adults with growth hormone deficiency due to low secretion of GH for a condition called hypothalamic disease.

Since the studies conducted in England, Sweden and Denmark in 1985 show aging is a pituitary disease, the FDA approval of Somatropin therapy now allows physicians to prescribe it to those with low levels of IGF-1.

Eli Lilly secured FDA approval for Somatropin replacement therapy because their trials showed that it resulted in many attributes that would lead to a more youthful lifestyle.

The studies showed an increase in muscle mass, decrease in body fat, increase in exercise capacity, increase in energy levels, organ rejuvenation, hair growth, increased memory, tighter skin, and much more. This helped patients live a more fulfilled, energetic lifestyle.

Considering these studies and trials, it can be concluded that professionals recommend taking Somatropin in their 30’s to prevent aging and diseases. Starting injections of Somatropin in your 50’s is more difficult since it is reversing the aging process instead of preventing it, however, it is still recommended and successful.